In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy.
Dr Park and colleagues from Korea summarized the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of Helicobacter pylori infection.
The researchers conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords “vonoprazan,” “takecab”, “TAK-438,” “potassium,” “competitive,” “potassium-competitive,” “Helicobacter,” and “pylori.”
Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies.
|Helicobacter pylori eradication rate was 88% in the vonoprazan-based triple therapy |
|Alimentary Pharmacology & Therapeutics|
The research team found 10 studies evaluated 10,644 patients.
The crude Helicobacter pylori eradication rate determined by intention-to-treat analysis was 88% and 73% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively.
The researchers found that the eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy.
In addition, the team observed no significant difference in dropout rate due to adverse event between the regimens.
The research team noted that the incidence of any adverse events also did not differ between the regimens.
Dr Park's team concludes, "The vonoprazan-based triple therapy showed superior efficacy in terms of Helicobacter pylori eradication as compared to the PPI-based triple therapy."
"In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events."